Robert C Block1, Linxi Liu2, David M Herrington3, Shue Huang4, Michael Y Tsai5, Timothy D O'Connell6, Gregory C Shearer7. 1. Department of Public Health Sciences, University of Rochester School of Medicine and Dentistry, Rochester, New York; Cardiology Division, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York. 2. Department of Public Health Sciences, University of Rochester School of Medicine and Dentistry, Rochester, New York. 3. Cardiology, Epidemiology and Prevention, Wake Forest University, Winston-Salem, North Carolina. 4. Department of Nutritional Sciences, Pennsylvania State University, University Park, Pennsylvania. 5. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota. 6. Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, Minnesota. Electronic address: tdoconne@umn.edu. 7. Department of Nutritional Sciences, Pennsylvania State University, University Park, Pennsylvania. Electronic address: gcs13@psu.edu.
Abstract
OBJECTIVES: The aim of this study was to determine if plasma eicosapentaenoic acid (EPA) abundance (%EPA) is associated with reduced hazard for primary heart failure (HF) events in the MESA (Multi-Ethnic Study of Atherosclerosis) trial. BACKGROUND: Clinical trials suggest that omega-3 polyunsaturated fatty acids (ω3 PUFAs) prevent sudden death in coronary heart disease and HF, but this is controversial. In mice, the authors demonstrated that the ω3 PUFA EPA prevents contractile dysfunction and fibrosis in an HF model, but whether this extends to humans is unclear. METHODS: In the MESA cohort, the authors tested if plasma phospholipid EPA predicts primary HF incidence, including HF with reduced ejection fraction (EF) (EF <45%) and HF with preserved EF (EF ≥45%) using Cox proportional hazards modeling. RESULTS: A total of 6,562 participants 45 to 84 years of age had EPA measured at baseline (1,794 black, 794 Chinese, 1,442 Hispanic, and 2,532 white; 52% women). Over a median follow-up period of 13.0 years, 292 HF events occurred: 128 HF with reduced EF, 110 HF with preserved EF, and 54 with unknown EF status. %EPA in HF-free participants was 0.76% (0.75% to 0.77%) but was lower in participants with HF at 0.69% (0.64% to 0.74%) (p = 0.005). Log %EPA was associated with lower HF incidence (hazard ratio: 0.73 [95% confidence interval: 0.60 to 0.91] per log-unit difference in %EPA; p = 0.001). Adjusting for age, sex, race, body mass index, smoking, diabetes mellitus, blood pressure, lipids and lipid-lowering drugs, albuminuria, and the lead fatty acid for each cluster did not change this relationship. Sensitivity analyses showed no dependence on HF type. CONCLUSIONS: Higher plasma EPA was significantly associated with reduced risk for HF, with both reduced and preserved EF. (Multi-Ethnic Study of Atherosclerosis [MESA]; NCT00005487).
OBJECTIVES: The aim of this study was to determine if plasma eicosapentaenoic acid (EPA) abundance (%EPA) is associated with reduced hazard for primary heart failure (HF) events in the MESA (Multi-Ethnic Study of Atherosclerosis) trial. BACKGROUND: Clinical trials suggest that omega-3 polyunsaturated fatty acids (ω3 PUFAs) prevent sudden death in coronary heart disease and HF, but this is controversial. In mice, the authors demonstrated that the ω3 PUFA EPA prevents contractile dysfunction and fibrosis in an HF model, but whether this extends to humans is unclear. METHODS: In the MESA cohort, the authors tested if plasma phospholipidEPA predicts primary HF incidence, including HF with reduced ejection fraction (EF) (EF <45%) and HF with preserved EF (EF ≥45%) using Cox proportional hazards modeling. RESULTS: A total of 6,562 participants 45 to 84 years of age had EPA measured at baseline (1,794 black, 794 Chinese, 1,442 Hispanic, and 2,532 white; 52% women). Over a median follow-up period of 13.0 years, 292 HF events occurred: 128 HF with reduced EF, 110 HF with preserved EF, and 54 with unknown EF status. %EPA in HF-free participants was 0.76% (0.75% to 0.77%) but was lower in participants with HF at 0.69% (0.64% to 0.74%) (p = 0.005). Log %EPA was associated with lower HF incidence (hazard ratio: 0.73 [95% confidence interval: 0.60 to 0.91] per log-unit difference in %EPA; p = 0.001). Adjusting for age, sex, race, body mass index, smoking, diabetes mellitus, blood pressure, lipids and lipid-lowering drugs, albuminuria, and the lead fatty acid for each cluster did not change this relationship. Sensitivity analyses showed no dependence on HF type. CONCLUSIONS: Higher plasma EPA was significantly associated with reduced risk for HF, with both reduced and preserved EF. (Multi-Ethnic Study of Atherosclerosis [MESA]; NCT00005487).
Authors: Timothy D O'Connell; Katherine A Murphy; Naixin Zhang; Sara J Puccini; Chastity L Healy; Brian A Harsch; Michael J Zhang; Gregory C Shearer Journal: Physiology (Bethesda) Date: 2022-08-09
Authors: JoAnn E Manson; Shari S Bassuk; Nancy R Cook; I-Min Lee; Samia Mora; Christine M Albert; Julie E Buring Journal: Circ Res Date: 2020-01-02 Impact factor: 17.367
Authors: Clemens Wittenbecher; Fabian Eichelmann; Estefanía Toledo; Marta Guasch-Ferré; Miguel Ruiz-Canela; Jun Li; Fernando Arós; Chih-Hao Lee; Liming Liang; Jordi Salas-Salvadó; Clary B Clish; Matthias B Schulze; Miguel Ángel Martínez-González; Frank B Hu Journal: Circ Res Date: 2020-12-04 Impact factor: 17.367
Authors: Andrew Elagizi; Carl J Lavie; Evan O'Keefe; Keri Marshall; James H O'Keefe; Richard V Milani Journal: Nutrients Date: 2021-01-12 Impact factor: 5.717